SEC Form SC 13G/A filed by iRadimed Corporation (Amendment)
$IRMD
Medical/Dental Instruments
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/12/2023 | $50.00 | Buy | Lake Street |
4 - IRADIMED CORP (0001325618) (Issuer)
4 - IRADIMED CORP (0001325618) (Issuer)
4 - IRADIMED CORP (0001325618) (Issuer)
Reports record revenue of $21.2 million for the third quarter of 2025, an increase of $2.9 million, or 16%, compared to the same period in 2024.Reports record GAAP diluted EPS of $0.43 and non-GAAP diluted EPS of $0.47 for the third quarter of 2025, which are increases of 8% and 9%, respectively, compared to the same period in 2024.Raises full-year guidance to revenue of $82.5 million to $83.5 million and GAAP diluted EPS to $1.68 to $1.72.Declares a regular quarterly cash dividend of $0.17 per share of common stock for the fourth quarter of 2025, payable on November 25, 2025. ORLANDO, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company" or "Iradimed") (NASDAQ:IRMD)
ORLANDO, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2025 third quarter financial results before the market opens on Monday, November 3, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register-conf.media-server.com/register/BIb4c35afb95154b348a034716bd7b99d8. Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available real-
ORLANDO, Fla., Sept. 02, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION ("Iradimed" or the "Company") (NASDAQ:IRMD), a leader in innovative medical devices for Magnetic Resonance Imaging ("MRI")-compatible patient monitoring and infusion systems, today announced a Board of Directors (the "Board") transition. Anthony Vuoto has retired from his position as a director, effective August 27, 2025, after deciding it is time to step away following many years of dedicated service. Effective September 2, 2025, the Board has appointed Joe Kiani, Masimo founder and renowned medical technology innovator and entrepreneur, to fill the vacancy on the Board. Anthony Vuoto served as a director of Iradime
10-Q - IRADIMED CORP (0001325618) (Filer)
8-K - IRADIMED CORP (0001325618) (Filer)
10-K/A - IRADIMED CORP (0001325618) (Filer)
Lake Street initiated coverage of iRadimed with a rating of Buy and set a new price target of $50.00
WINTER SPRINGS, Fla., Oct. 06, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) today announced the appointment of Hilda Scharen-Guivel to the Iradimed Board of Directors, effective October 4, 2022. Following the appointment of Ms. Scharen-Guivel, the Board will comprise five directors, three of whom are independent. "We are pleased to welcome Hilda Scharen-Guivel to the Iradimed Board," said Roger Susi, President and Chief Executive Officer of the Company. "Hilda's deep experience in regulatory oversight in the medical device industry will be invaluable to Iradimed as we develop new products and grow our business to better serve patients." Ms. Scharen-Guivel,
Perimeter Medical Imaging AI, Inc. (TSXV:PINK)(OTC:PYNKF) (FSE:4PC) ("Perimeter" or the "Company"), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today announced the appointment of Chris Scott as Chief Financial Officer, effective immediately. Jeremy Sobotta, Perimeter's Chief Executive Officer stated, "We are pleased to welcome Chris to the Perimeter leadership team. Chris is a collaborative leader who brings a wealth of public company experience directly relevant to Perimeter as we continue to execute on our commercial, clinical, and corporate development goals. Previously
Reports record revenue of $21.2 million for the third quarter of 2025, an increase of $2.9 million, or 16%, compared to the same period in 2024.Reports record GAAP diluted EPS of $0.43 and non-GAAP diluted EPS of $0.47 for the third quarter of 2025, which are increases of 8% and 9%, respectively, compared to the same period in 2024.Raises full-year guidance to revenue of $82.5 million to $83.5 million and GAAP diluted EPS to $1.68 to $1.72.Declares a regular quarterly cash dividend of $0.17 per share of common stock for the fourth quarter of 2025, payable on November 25, 2025. ORLANDO, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company" or "Iradimed") (NASDAQ:IRMD)
ORLANDO, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2025 third quarter financial results before the market opens on Monday, November 3, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register-conf.media-server.com/register/BIb4c35afb95154b348a034716bd7b99d8. Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available real-
Announces Regular Quarterly Cash Dividend of $0.17 Per Share Raises Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $20.4 million for the second quarter of 2025, an increase of $2.5 million, or 14%, compared to the same period in 2024.Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the second quarter of 2025, which are increases of 18% and 17%, respectively, compared to the same period in 2024.Declares a regular quarterly cash dividend of $0.17 per share of common stock for the third quarter of 2025, payable on August 28, 2025. ORLANDO, Fla., Aug. 01, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company" or "Iradimed") (NASDAQ
SC 13G/A - IRADIMED CORP (0001325618) (Subject)
SC 13G/A - IRADIMED CORP (0001325618) (Subject)
SC 13G/A - IRADIMED CORP (0001325618) (Subject)